{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T10:41:39Z","timestamp":1775212899764,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1038\/eye.2016.132","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T13:04:53Z","timestamp":1467378293000},"page":"1187-1194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study"],"prefix":"10.1038","volume":"30","author":[{"given":"M E","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"O\u2019Halloran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"VanderVeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Roarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Plager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Markwardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Gedif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S R","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"issue":"6","key":"BFeye2016132_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaophthalmol.2014.531","volume":"132","author":"SR Lambert","year":"2014","unstructured":"Infant Aphakia Treatment Study Group Infant Aphakia Treatment Study Group Lambert SR Infant Aphakia Treatment Study Group Lynn MJ Infant Aphakia Treatment Study Group Hartmann EE Infant Aphakia Treatment Study Group DuBois L Infant Aphakia Treatment Study Group Drews-Botsch C et al. Comparison of contact lens and intraocular lens correction of monocular aphakia during infancy: a randomized clinical trial of HOTV optotype acuity at age 4.5 years and clinical findings at age 5 years. JAMA Ophthalmol 2014; 132 (6): 676\u2013682.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"BFeye2016132_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajo.2014.09.028","volume":"159","author":"EE Hartmann","year":"2014","unstructured":"Hartmann EE, Stout AU, Lynn JL, Yen KG, Kruger SJ, Lambert SR et al. Stereopsis results at 4.5 years of age in the Infant Aphakia Treatment Study. Am J Ophthalmol 2014; 159 (1): 64\u201370.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"BFeye2016132_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/ICU.0b013e328332f575","volume":"21","author":"M Jancevski","year":"2010","unstructured":"Jancevski M, Foster CS . Cataracts and uveitis. Curr Opin Ophthalmol 2010; 21 (1): 10\u201314.","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"BFeye2016132_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/ICU.0b013e32835b0716","volume":"24","author":"BL Shoss","year":"2013","unstructured":"Shoss BL, Tsai LM . Postoperative care in cataract surgery. Curr Opin Ophthalmol 2013; 24 (1): 66\u201373.","journal-title":"Curr Opin Ophthalmol"},{"key":"BFeye2016132_CR5","unstructured":"Devgan U Inflammation and pain control in cataract surgery. Topics in Ocular Antiflammatories. Continuing Medical Education: University of Florida, USA 2003 (2)."},{"issue":"2","key":"BFeye2016132_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0039-6257(92)90073-3","volume":"37","author":"DJ Apple","year":"1992","unstructured":"Apple DJ, Solomon KD, Tetz MR, Assia EI, Holland EY, Legler UF et al. Posterior capsule opacification. Surv Ophthalmol 1992; 37 (2): 73\u2013116.","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"BFeye2016132_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/archopht.1966.03850010648005","volume":"76","author":"JD Gass","year":"1966","unstructured":"Gass JD, Norton EW . Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study. Arch Ophthalmol 1966; 76 (5): 646\u2013661.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"BFeye2016132_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0886-3350(01)01028-8","volume":"28","author":"BM Hosal","year":"2002","unstructured":"Hosal BM, Biglan AW . Risk factors for secondary membrane formation after removal of pediatric cataract. J Cataract Refract Surg 2002; 28 (2): 302\u2013309.","journal-title":"J Cataract Refract Surg"},{"issue":"1","key":"BFeye2016132_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jcrs.2008.09.024","volume":"35","author":"MS Korenfeld","year":"2009","unstructured":"Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS, Difluprednate Ophthalmic Emulsion 0.05% Study Group. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg 2009; 35 (1): 26\u201334.","journal-title":"J Cataract Refract Surg"},{"issue":"10","key":"BFeye2016132_CR10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12325-013-0059-7","volume":"30","author":"RK Rajpal","year":"2013","unstructured":"Rajpal RK, Fong R, Comstock TL . Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies. Adv Ther 2013; 30 (10): 907\u2013923.","journal-title":"Adv Ther"},{"issue":"11","key":"BFeye2016132_CR11","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00417-008-0908-2","volume":"246","author":"K Lorenz","year":"2008","unstructured":"Lorenz K, Dick B, Jehkul A, Auffahrt GU . Inflammatory response after phacoemulsification treated with 0.5% prednisolone acetate or vehicle. Graefes Arch Clin Exp Ophthalmol 2008; 246 (11): 1617\u20131622.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"BFeye2016132_CR12","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1167\/iovs.13-12660","volume":"55","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS . Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci 2014; 55 (5): 2993\u20133002.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2016132_CR13","unstructured":"Alcon. DUREZOL\u00ae Product information. 2013."},{"issue":"5","key":"BFeye2016132_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/jop.2010.0059","volume":"26","author":"CS Foster","year":"2010","unstructured":"Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS . Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther 2010; 26 (5): 475\u2013483.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"BFeye2016132_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ajo.2014.07.031","volume":"158","author":"DA Plager","year":"2014","unstructured":"Plager DA, Lynn MJ, Buckley EG, Wilson ME, Lambert SR et alInfant Aphakia Treatment Study G. Complications in the first 5 years following cataract surgery in infants with and without intraocular lens implantation in the infant aphakia treatment study. Am J Ophthalmol 2014; 158 (5): 892\u2013898 e2.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2016132_CR16","unstructured":"FDA. Clinical pharmacology review: Difluprednate Ophthalmic Emulsion 0.05%. 2014 (May 2014). Available from \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM353857.pdf\n                    \n                  ."},{"issue":"44","key":"BFeye2016132_CR17","first-page":"51","volume":"9","author":"M Jancevski","year":"2010","unstructured":"Jancevski M, Foster CS . Cataracts and uveitis. Discov Med 2010; 9 (44): 51\u201354.","journal-title":"Discov Med"},{"issue":"12","key":"BFeye2016132_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.optm.2010.09.001","volume":"81","author":"K Meehan","year":"2010","unstructured":"Meehan K, Vollmer L, Sowka J . Intraocular pressure elevation from topical difluprednate use. Optometry 2010; 81 (12): 658\u2013662.","journal-title":"Optometry"},{"key":"BFeye2016132_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2147\/OPTH.S10696","volume":"4","author":"S Smith","year":"2010","unstructured":"Smith S, Lorenz D, Peace J, McLeod K, Crockett RS, Vogel R . Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery. Clin Ophthalmol 2010; 4: 983\u2013991.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"BFeye2016132_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ajo.2011.10.008","volume":"153","author":"MA Slabaugh","year":"2012","unstructured":"Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN . Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol 2012; 153 (5): 932\u2013938.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"BFeye2016132_CR21","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1097\/IAE.0000000000000215","volume":"34","author":"KW Jeng","year":"2014","unstructured":"Jeng KW, Fine HF, Wheatley HM, Roth D, Connors DB, Prenner JL . Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate. Retina 2014; 34 (10): 1990\u20131996.","journal-title":"Retina"},{"issue":"4","key":"BFeye2016132_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/IJG.0000000000000209","volume":"25","author":"S Kaur","year":"2016","unstructured":"Kaur S, Dhiman I, Kaushik S, Raj S, Pandav SS . Outcome of ocular steroid hypertensive response in children. J Glaucoma 2016; 25 (4): 343\u2013347.","journal-title":"J Glaucoma"},{"key":"BFeye2016132_CR23","unstructured":"Lane S Considerations in the treatment of ocular inflammation: II. Loteprednol Etabonate Technical Paper 2009; II."},{"key":"BFeye2016132_CR24","first-page":"23","volume":"8","author":"ZT Marlowe","year":"2014","unstructured":"Marlowe ZT, Davio SR . Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%). Clin Ophthalmol 2014; 8: 23\u201329.","journal-title":"Clin Ophthalmol"},{"key":"BFeye2016132_CR25","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2147\/OPTH.S12441","volume":"4","author":"W Stringer","year":"2010","unstructured":"Stringer W, Bryant R . Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol 2010; 4: 1119\u20131124.","journal-title":"Clin Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2016132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2016132","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2016132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:27:38Z","timestamp":1684430858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2016132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["BFeye2016132"],"URL":"https:\/\/doi.org\/10.1038\/eye.2016.132","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]},"assertion":[{"value":"1 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KM and KG are employees and own stocks\/shares of Alcon Laboratories, Inc. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}